Intellia Therapeutics NTLA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $134.7M+6.2% | $155.46M-17.8% | $193.39M+60.5% | $156.17M+19.4% | $126.88M-26.2% | ||
| $241.29M-36.0% | $294.42M-28.6% | $317.66M-40.9% | $303.48M-45.8% | $376.87M-39.1% | ||
| $9.13M-13.1% | $9.47M+11.2% | $11.05M+24.8% | $11.35M-7.9% | $10.5M-71.2% | ||
| $81.33M+119% | $68.36M+129% | $59.85M+36.2% | $24.94M-53.7% | $37.14M-34.1% | ||
| $466.45M-15.4% | $527.71M-17.5% | $581.94M-18.1% | $495.95M-34.5% | $551.39M-37.6% | ||
| $15.52M-38.2% | $17.67M-35.5% | $20.42M-29.0% | $22.81M-24.7% | $25.12M-21.7% | ||
| $97.54M-29.3% | $105.96M-51.7% | $117.88M+17.5% | $129.05M+22.4% | $137.98M+25.0% | ||
| $38.01M-44.4% | $35.54M-19.7% | $46.22M-1.2% | $80.24M+61.0% | $68.32M-3.7% | ||
| $758.78M-23.1% | $842.13M-29.3% | $925.28M-21.1% | $898.89M-24.6% | $986.16M-21.7% | ||
| $18.8M+52.1% | $20.25M+38.8% | $13.26M+0.9% | $9.8M-47.9% | $12.36M-9.7% | ||
| $37.92M-7.1% | $49.86M-9.9% | $40.84M-20.2% | $41.55M-7.9% | $40.81M-5.7% | ||
| $630K-97.0% | $7.29M-64.7% | $12.25M-44.7% | $17.15M-22.7% | $20.66M-6.9% | ||
| $19.1M-50.7% | $26.48M+30.8% | $27.38M+42.8% | $26.99M+42.3% | $38.76M+107% | ||
| $76.45M-32.1% | $103.88M-6.3% | $93.73M-11.3% | $95.5M-9.1% | $112.59M+15.0% | ||
| $61.4M-23.7% | $66.85M-64.8% | $70.59M-14.4% | $75.6M-13.4% | $80.49M-12.6% | ||
| $80.49M— | $93.33M— | $97.97M— | —— | —— | ||
| $137.84M-33.2% | $170.73M-46.5% | $176.85M-16.1% | $183.64M-16.7% | $206.24M— | ||
| $12K+20.0% | $12K+20.0% | $12K+20.0% | $10K0.0% | $10K0.0% | ||
| $3.31B+7.7% | $3.26B+6.9% | $3.24B+7.8% | $3.11B+7.7% | $3.07B+9.6% | ||
| -$2.69B-17.2% | -$2.59B-19.0% | -$2.49B-21.8% | -$2.39B-25.1% | -$2.29B-29.8% | ||
| -$240K-123% | $1.03M+70.6% | $990K-70.0% | $653K+157% | $1.06M+212% | ||
| $620.94M-20.4% | $671.39M-23.0% | $748.42M-22.3% | $715.26M-26.3% | $779.92M-24.7% | ||
| $758.78M-23.1% | $842.13M-29.3% | $925.28M-21.1% | $898.89M-24.6% | $986.16M-21.7% | ||
| $241.29M-36.0% | $294.42M-28.6% | $317.66M-40.9% | $303.48M-45.8% | $376.87M-39.1% | ||
| $97.54M-29.3% | $105.96M-51.7% | $117.88M+17.5% | $129.05M+22.4% | $137.98M+25.0% | ||
| $38.01M-44.4% | $35.54M-19.7% | $46.22M-1.2% | $80.24M+61.0% | $68.32M-3.7% | ||
| $97.54M-29.3% | $105.96M-51.7% | $117.88M+17.5% | $129.05M+22.4% | $137.98M+25.0% | ||
| $97.54M-29.3% | $105.96M-51.7% | $117.88M+17.5% | $129.05M+22.4% | $137.98M+25.0% | ||
| $37.92M-7.1% | $49.86M-9.9% | $40.84M-20.2% | $41.55M-7.9% | $40.81M-5.7% | ||
| $37.92M-7.1% | $49.86M-9.9% | $40.84M-20.2% | $41.55M-7.9% | $40.81M-5.7% | ||
| $80.49M-32.5% | $93.33M-55.6% | $97.97M-3.6% | $102.59M-3.5% | $119.25M+7.6% | ||
| $3.31B+7.7% | $3.26B+6.9% | $3.24B+7.8% | $3.11B+7.7% | $3.07B+9.6% | ||
| $12K+20.0% | $12K+20.0% | $12K+20.0% | $10K0.0% | $10K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Intellia Therapeutics cover its short-term obligations?
- Its current ratio is 6.10 — current assets exceed current liabilities.
- Where does Intellia Therapeutics's balance sheet data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.